HALOZYME THERAPEUTICS, INC. - 8-K Filing

Halozyme Therapeutics proposes $1.05B offering of convertible senior notes due 2033 (Items: 8.01 Other EventsOn September 16, 2026, Halozyme Therapeutics, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $HALO

Read the full article at SEC EDGAR

More Regulatory news